Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 3/20 | 0.56 |
| ▸ | TLR1 | Q15399 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 13/20 | 0.50 |
| ▸ | MAOB | P27338 | 7/20 | 0.50 |
| ▸ | MAOA | P21397 | 4/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.46 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL529662 | 1.00 | TLR2 (0.56) | TLR2TLR1SMN1; SMN2NPSR1KDM1A | |
| SCHEMBL2562813 | 1.00 | TLR2 (0.56) | TLR2TLR1SMN1; SMN2NPSR1KDM1A | |
| SCHEMBL11888836 | 0.84 | KDM1A (0.63) | KDM1AMAOBMAOA | |
| SCHEMBL11888872 | 0.84 | SMN1; SMN2 (0.54) | TLR2TLR1SMN1; SMN2NPSR1KDM1A | |
| SCHEMBL11888871 | 0.84 | SMN1; SMN2 (0.54) | TLR2TLR1SMN1; SMN2NPSR1KDM1A | |
| SCHEMBL7980208 | 0.83 | SMN1; SMN2 (0.73) | TLR2TLR1SMN1; SMN2NPSR1KDM1A | |
| SCHEMBL6153775 | 0.83 | SMN1; SMN2 (0.73) | TLR2TLR1SMN1; SMN2NPSR1KDM1A | |
| SCHEMBL6154005 | 0.83 | SMN1; SMN2 (0.73) | TLR2TLR1SMN1; SMN2NPSR1KDM1A | |
| SCHEMBL3457343 | 0.83 | SMN1; SMN2 (0.73) | TLR2TLR1SMN1; SMN2NPSR1KDM1A | |
| SCHEMBL19357558 | 0.83 | KDM1A (0.65) | KDM1AMAOBMAOARCOR1KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495349-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2023-06-28 | — | — | EP | disclosed |
| EP-3736265-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2020-11-11 | — | — | EP | disclosed |
| EP-2768805-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2020-03-25 | — | — | EP | disclosed |
| EP-2907802-B1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2019-06-25 | — | — | US | disclosed |
| EP-3495349-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2019-06-12 | — | — | EP | disclosed |
| EP-2598480-B1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2019-04-24 | — | — | EP | disclosed |
| EP-2486002-B1 | SUBSTITUTED HETEROARYL- AND ARYL- CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | ORYZON GENOMICS SA (ES) | 2019-03-27 | — | — | EP | disclosed |
| US-10233178-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | ORYZON GENOMICS, S.A. (ES) | 2019-03-19 | — | — | US | disclosed |
| US-10202330-B2 | Lysine specific demethylase-1 inhibitors and their use | ORYZON GENOMICS, SA (ES) | 2019-02-12 | — | — | US | disclosed |
| WO-2013057322-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2013-04-25 | — | — | WO | disclosed |
| US-20130090386-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | ORYZON GENOMICS S.A. | 2013-04-11 | — | — | US | disclosed |
| EP-2560947-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2013-02-27 | — | — | EP | disclosed |
| US-20120283266-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | ORYZON GENOMICS S.A. (ES) | 2012-11-08 | — | — | US | disclosed |
| EP-2486002-A1 | SUBSTITUTED HETEROARYL- AND ARYL- CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2012-08-15 | — | — | EP | disclosed |
| EP-2480528-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2012-08-01 | — | — | EP | disclosed |
| WO-2012013727-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012013728-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2012-02-02 | — | — | WO | disclosed |
| WO-2011131697-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | ORYZON GENOMICS S.A. (ES) | 2011-10-27 | — | — | WO | disclosed |
| WO-2010043721-A1 | OXIDASE INHIBITORS AND THEIR USE | ORYZON GENOMICS, S.A. (ES) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233178-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | KDM6A, KDM1B, KDM1A | TLR2 3068/4885TLR1 3715/4885SMN1; SMN2 1680/4885 |
| US-20120283266-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | JMJD6, KDM3A, KDM1A | TLR2 4285/4885TLR1 3808/4885SMN1; SMN2 4326/4885 |
| US-10202330-B2 | Lysine specific demethylase-1 inhibitors and their use | KDM1A, KDM1B, KDM3A | TLR2 3996/4885TLR1 3468/4885SMN1; SMN2 4142/4885 |
| US-20130090386-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | KDM1A, KDM1B, KDM3A | TLR2 3996/4885TLR1 3468/4885SMN1; SMN2 4142/4885 |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | TLR2 3342/4885TLR1 3509/4885SMN1; SMN2 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.